Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

被引：0

作者：

Dietrich, S. ^{[1
]}

Hutchings, M. ^{[2
,3
]}

Avigdor, A. ^{[4
,5
]}

Sureda, A. ^{[6
]}

Terol, M. J. ^{[7
]}

Bosch, F. ^{[8
]}

Corradini, P. ^{[9
,10
]}

Larsen, Stauffer T. ^{[11
]}

Dominguez, Rueda A. ^{[12
]}

Skarbnik, A. ^{[13
]}

Jorgensen, J. ^{[14
]}

Goldschmidt, N. ^{[15
]}

Gurion, R. ^{[16
,17
]}

Zinzani, P. L. ^{[18
,19
]}

Pinto, A. ^{[20
]}

Cordoba, R. ^{[21
]}

Bottos, A. ^{[22
]}

Huang, Z. ^{[23
]}

Simko, S. ^{[24
]}

Relf, J. ^{[25
]}

de L'Etang, Filezac A. ^{[22
]}

Sellam, G. ^{[22
]}

Gritti, G. ^{[26
,27
]}

机构：

[1] Heidelberg Univ Hosp, Clin Hematol, Oncol, Rheumatol, Heidelberg, Germany

[2] Rigshosp, Dept Hematol, Copenhagen, Denmark

[3] Rigshosp, Phase Unit 1, Copenhagen, Denmark

[4] Sheba Med Ctr, Inst Hematol, Ramat Gan, Israel

[5] Tel Aviv Univ, Tel Aviv, Israel

[6] Univ Barcelona, Dept Clin Hematol, Barcelona, Spain

[7] Univ Valencia, Hosp Clin Univ INCLIVA, Dept Hematol, Valencia, Spain

[8] Univ Hosp Vall dHebron, Dept Hematol, Barcelona, Spain

[9] Univ Milan, Milan, Italy

[10] Fdn IRCCS Ist Nazl Tumori, Dept Hematol, Milan, Italy

[11] Odense Univ Hosp, Dept Hematol, Odense, Denmark

[12] Reg & Virgen de la Victoria Univ Hosp, Med Oncol Interctr Unit, Malaga, Spain

[13] Novant Hlth Canc Inst, Lymphoma & CLL Program, Charlotte, NC USA

[14] Aarhus Univ Hosp, Dept Clin Med, Dept Haematol, Aarhus, Denmark

[15] Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel

[16] Rabin Med Ctr, Inst Hematol, Petah Tiqwa, Israel

[17] Tel Aviv Univ, Tel Aviv, Israel

[18] Univ Bologna, IRCCS Azienda Univ Hosp, Bologna Inst Hematol, Bologna, Italy

[19] Univ Bologna, Dept Specialist Diagnost & Expt Med, Bologna, Italy

[20] Natl Canc Inst Fdn G Pascale IRCCS, Dept Hematol, Neapel, Italy

[21] Fdn Jimenez Diaz Univ Hosp, Dept Hematol, Madrid, Spain

[22] F Hoffmann La Roche Ltd, Basel, Switzerland

[23] F Hoffmann La Roche Ltd, Shanghai, Peoples R China

[24] Genentech Inc, San Francisco, CA USA

[25] F Hoffmann La Roche Ltd, Welwyn Garden City, England

[26] Azienda Osped Papa Giovanni XXIII, Hematol Unit, Bergamo, Italy

[27] Azienda Osped Papa Giovanni XXIII, Bone Marrow Transplant Unit, Bergamo, Italy

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P404

引用

页码：209 / 209

页数：1

共 50 条

[1] Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Hutchings, Martin
Sureda, Anna
Terol, Maria Jose
Albareda, Francesc Bosch
Corradini, Paolo
Larsen, Thomas Stauffer
Dominguez, Antonio Rueda
Panchal, Anesh
Bottos, Alessia
Carlile, David
Wang, Yanjie
De L'Etang, Audrey Filezac
Tandon, Maneesh
Sellam, Gila
Gritti, Giuseppe
BLOOD, 2021, 138
[2] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
Dietliker, N.
Kiesel, H.
Mueller, R.
Mueller, A. M.
Manz, M.
Zenz, T.
Rosler, W.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
[3] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, Laurie H.
Herrera, Alex F.
Flowers, Christopher R.
Kamdar, Manali K.
McMillan, Andrew
Hertzberg, Mark
Assouline, Sarit
Kim, Tae Min
Kim, Won Seog
Ozcan, Muhit
Hirata, Jamie
Penuel, Elicia
Paulson, Joseph N.
Cheng, Ji
Ku, Grace
Matasar, Matthew J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
[4] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
Dietliker, N.
Kiesel, H.
Mueller, R.
Mueller, A. M.
Manz, M. G.
Zenz, T.
Rosler, W.
SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
[5] Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Preliminary Phase Ib/II Data supports the controllable Safety and encouraging Efficacy in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL)
Hutchings, M.
Sureda, A.
Terol, M. J.
Bosch, F.
Corradini, P.
Stauffer, Larsen T.
Rueda, Dominguez A.
Panchal, A.
Bottos, A.
Carlile, D.
Wang, Y.
de L'Etang, Filezac A.
Tandon, M.
Sellam, G.
Gritti, G.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 54 - 54
[6] Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Shingleton, Jennifer R.
Dave, Sandeep S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 166 - +
[7] Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
Sehn, L. H.
McMillan, A.
Matasar, M. J.
Flowers, C. R.
Kamdar, M.
Hertzberg, M.
Assouline, S.
Kim, T. M.
Kim, W. S.
Ozcan, M.
Croft, B.
Herrera, A. F.
Hirata, J.
Cheng, J.
Ku, G.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 93 - 94
[8] POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Haioun, Corinne
Matasar, Matthew J.
Sancho, Juan-Manuel
Viardot, Andreas
Hernandez, Juana
Perretti, Thomas
McMillan, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Primary Analysis of a Phase Ib/II Study
Budde, L. Elizabeth
Olszewski, Adam J.
Assouline, Sarit
Lossos, Izidore S.
Diefenbach, Catherine
Kamdar, Manali
Ghosh, Nilanjan
Modi, Dipenkumar
Sabry, Waleed
Naik, Seema
Mehta, Amitkumar
Nakhoda, Shazia K.
Smith, Stephen D.
Dorritie, Kathleen
Jia, Ting
Pham, Song
Huw, Ling-Yuh
Wu, Hao
To, Iris
Wei, Michael C.
Chavez, Julio C.
BLOOD, 2023, 142
[10] Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Matasar, Matthew J.
Haioun, Corinne
Sancho, Juan-Manuel
Viardot, Andreas
Izquierdo, Antonia Rodriguez
Martin, Eva Maria Donato
Garcia-Sancho, Alejandro Martin
Sandoval-Sus, Jose David
Tilly, Herve
Vandenberghe, Elizabeth
Hirata, Jamie
Choudhry, Priya
Chang, Yi Meng
Musick, Lisa
McMillan, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →